Xiebai bining decoction attenuates renal fibrosis in hyperuricemic nephropathy alongside changes in FUNDC1/LC3B autophagy markers and TGF-β1/Smad3 signaling

Background Hyperuricemic nephropathy (HN), a major renal complication of hyperuricemia (HUA), is closely associated with renal tubulointerstitial fibrosis. Dysregulated transforming growth factor-β1 (TGF-β1)/Smad3 signaling and impaired mitochondrial quality control may contribute to HN progression. This study evaluated the effects of Xiebai Bining Decoction (XBD) on HN-associated renal fibrosis and examined accompanying changes in FUN14 domain-containing protein 1 (FUNDC1)/LC3B autophagy-related markers and TGF-β1/Smad3 signaling-associated measurements. Methods An HN mouse model was induced by potassium oxonate combined with adenine. Mice were treated with XBD, febuxostat, the autophagy inhibitor 3-methyladenine (3-MA), or XBD plus 3-MA. Serum uric acid (SUA), serum creatinine (Scr), and blood urea nitrogen (BUN) were measured, and renal histopathology and extracellular matrix (ECM) deposition were evaluated. FUNDC1, microtubule-associated protein 1 light chain 3B (LC3B), and TGF-β1/Smad3 signaling-related proteins were examined by Western blotting, immunofluorescence staining, immunohistochemical staining, enzyme-linked immunosorbent assay (ELISA), and transmission electron microscopy. Results XBD reduced SUA, Scr, and BUN levels, improved renal morphology, and alleviated renal tubular injury, ECM deposition, and changes in epithelial and mesenchymal markers in HN mice. XBD treatment was accompanied by higher FUNDC1 and LC3B-related measurements and more TEM-identified autophagosomal profiles; these readouts differed in the 3-MA-treated groups. XBD also decreased TGF-β1 content and downregulated TGF-β receptor type I (TGF-βRI) and phosphorylated Smad3 (p-Smad3) expression. Conclusion XBD treatment was associated with reduced renal injury and fibrosis, changes in FUNDC1- and LC3B-related autophagy markers, and attenuation of TGF-β1/Smad3 pathway-related responses in HN mice. These observations support associations between XBD-related renal protection and autophagy- and fibrosis-associated molecular responses without establishing a direct mechanistic relationship between them.

Authors

Institutions

Publication Details

Journal
Frontiers in Cell and Developmental Biology
Published
2026-11-05
DOI
https://doi.org/10.3389/fcell.2026.1975823
Primary Topic
Gout, Hyperuricemia, Uric Acid
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Xiebai bining decoction attenuates renal fibrosis in hyperuricemic nephropathy alongside changes in FUNDC1/LC3B autophagy markers and TGF-β1/Smad3 signaling

Min Li, Xue Xia, Kaiqing Li, Ying Tong
Frontiers in Cell and Developmental Biology
Gout, Hyperuricemia, Uric Acid
article

Xiebai bining decoction attenuates renal fibrosis in hyperuricemic nephropathy alongside changes in FUNDC1/LC3B autophagy markers and TGF-β1/Smad3 signaling

Min Li, Xue Xia, Kaiqing Li, Ying Tong
article en

Abstract

Background Hyperuricemic nephropathy (HN), a major renal complication of hyperuricemia (HUA), is closely associated with renal tubulointerstitial fibrosis. Dysregulated transforming growth factor-β1 (TGF-β1)/Smad3 signaling and impaired mitochondrial quality control may contribute to HN progression. This study evaluated the effects of Xiebai Bining Decoction (XBD) on HN-associated renal fibrosis and examined accompanying changes in FUN14 domain-containing protein 1 (FUNDC1)/LC3B autophagy-related markers and TGF-β1/Smad3 signaling-associated measurements. Methods An HN mouse model was induced by potassium oxonate combined with adenine. Mice were treated with XBD, febuxostat, the autophagy inhibitor 3-methyladenine (3-MA), or XBD plus 3-MA. Serum uric acid (SUA), serum creatinine (Scr), and blood urea nitrogen (BUN) were measured, and renal histopathology and extracellular matrix (ECM) deposition were evaluated. FUNDC1, microtubule-associated protein 1 light chain 3B (LC3B), and TGF-β1/Smad3 signaling-related proteins were examined by Western blotting, immunofluorescence staining, immunohistochemical staining, enzyme-linked immunosorbent assay (ELISA), and transmission electron microscopy. Results XBD reduced SUA, Scr, and BUN levels, improved renal morphology, and alleviated renal tubular injury, ECM deposition, and changes in epithelial and mesenchymal markers in HN mice. XBD treatment was accompanied by higher FUNDC1 and LC3B-related measurements and more TEM-identified autophagosomal profiles; these readouts differed in the 3-MA-treated groups. XBD also decreased TGF-β1 content and downregulated TGF-β receptor type I (TGF-βRI) and phosphorylated Smad3 (p-Smad3) expression. Conclusion XBD treatment was associated with reduced renal injury and fibrosis, changes in FUNDC1- and LC3B-related autophagy markers, and attenuation of TGF-β1/Smad3 pathway-related responses in HN mice. These observations support associations between XBD-related renal protection and autophagy- and fibrosis-associated molecular responses without establishing a direct mechanistic relationship between them.

Frontiers in Cell and Developmental BiologyVol. 14
Heilongjiang University of Chinese Medicine (CN), First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN), Affiliated Hospital of Shaanxi University of Chinese Medicine (CN)
Openalex Percentile: Top 13%
Gout, Hyperuricemia, Uric Acid
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon